NGENF News and Press, NervGen Pharma Corp From 05/16/22

Panel discussion will focus on the successful translation of NervGen's lead compound, NVG-291, from animals to humans Leading spinal cord injury experts on the panel include Drs. Jerry Silver, Monica Perez and James Guest NervGen will also present at the International Investment Forum ...

NervGen Pharma press release (OTCQX:NGENF): Q1 GAAP EPS of -$0.11. NervGen had cash and investments of $12.8 million as of March 31, 2022, compared to $5.0 million as of March 31, 2021. The net cash burn for Q1 2022 from operating activities was approximately $4.2 million. For further detai...

Safety Review Committee approves proceeding to third and highest dose cohort in multiple ascending dose portion of clinical trial No serious or severe adverse events reported in second dose cohort with NVG-291 Successful completion of the second cohort establishes a clear pathway to sele...

30 years of industry experience from CEO of Nasdaq-listed biotech to Vice President, Marketing at Pfizer Experience on 16 development stage products, 15 commercial stage products and numerous pre-clinical assets, in both start-up and large pharmaceutical companies Vancouver, British Columb...

Human subjects now being enrolled in the second cohort of multiple ascending dose portion of the study NVG-291 dose administered in the first cohort is already above the highest corresponding dose found to be efficacious in animal models and is substantially higher than the lower effective d...

Engages Apaton Finance to Provide Investor Relations Services in Europe Vancouver, British Columbia--(Newsfile Corp. - March 23, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutio...

NervGen Pharma (OTCQX:NGENF) received approval from A safety review committee to advance to the second cohort in the multiple ascending dose (MAD) portion of its phase 1 trial of NVG-291. The company said that following completion of the MAD portion of the study and ongoing toxicology studies...

The dose of NVG-291 in the first cohort is already above the highest corresponding dose that resulted in dramatic functional improvements in animal models Approval moves NervGen one step closer to Phase 1b/2 efficacy studies in Alzheimer's disease, multiple sclerosis and spinal cord injury p...

Vancouver, British Columbia--(Newsfile Corp. - February 28, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its...

Phase 1b/2a trial of NervGen’s lead compound, NVG-291, is based upon unprecedented, peer-reviewed animal studies demonstrating pronounced functional recovery from spinal cord injury “The ability of NVG-291 to demonstrate meaningful recovery in motor function, sen...